Table 1.
Anti-PD prescription patterns as first-line treatment in newly diagnosed PD patients during the 2008–2016 period.
Fig 1.
Number and percentage of patients prescribed L-dopa and non-ergot DA monotherapy as first-line treatment by age.
aGiven that the number of patients >95 years of age is small, the percentages of patients prescribed L-dopa and non-ergot DA are not reliable and are therefore not presented. DA, dopamine agonist; L-dopa, levodopa; PD, Parkinson’s disease.
Fig 2.
Period from initial diagnosis to prescription of first-line anti-PD drug (A) and continuation rate of first-line anti-PD drug from first treatment (B). Patients may be counted more than once because of hospital transfer. PD, Parkinson’s disease.
Fig 3.
Percentage of patients prescribed each type of anti-PD drug or combination over time.
Data are presented as cumulative percentages. Given the small number of patients who continued a prescribed anti-PD drug for more than 4 years after the index date, only 4-year data are presented. DA, dopamine agonist; L-dopa, levodopa; MAO-B, monoamine oxidase B; PD, Parkinson’s disease.